Imatinib therapy prior to myeloablative allogeneic stem cell transplantation
暂无分享,去创建一个
J. Zaucha | T. Gooley | W. Prejzner | A. Hellmann | J. Hołowiecki | S. Giebel | D. Szatkowski | K. Kałwak | J. Wojnar | T Krużel | J. Balon | Andrzej Hellmann | Damian Szatkowski | T. Kruzel | Joanna Balon
[1] J. Radich,et al. A Retrospective Study of Patients Treated with Imatinib Mesylate Prior to Allogeneic Hematopoietic Stem Cell Transplant. , 2004 .
[2] E. Kimby,et al. Combination Therapy with Rituximab and Fludarabine in Waldenstrom’s Macroglobulinemia. , 2004 .
[3] J. Radich,et al. Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia. , 2004, Hematology/oncology clinics of North America.
[4] T. Lipp,et al. Early prediction of response in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) treated with imatinib. , 2004, Blood.
[5] M. Freund,et al. Treosulfan and fludarabine: a new toxicity-reduced conditioning regimen for allogeneic hematopoietic stem cell transplantation. , 2004, Blood.
[6] Yoo-Jin Kim,et al. Minimal residual disease-based role of imatinib as a first-line interim therapy prior to allogeneic stem cell transplantation in Philadelphia chromosome-positive acute lymphoblastic leukemia. , 2003, Blood.
[7] W. Knopińska-Posłuszny,et al. Modification of the clonogenic capacity of bone marrow cells from normal individuals by the tyrosine kinase inhibitor STI571. , 2003, Clinical and laboratory haematology.
[8] J. Eary,et al. 166Ho-DOTMP plus melphalan followed by peripheral blood stem cell transplantation in patients with multiple myeloma: results of two phase 1/2 trials. , 2003, Blood.
[9] Susan Branford,et al. Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. , 2003, Blood.
[10] M. Minden,et al. Imatinib Mesylate (Gleevec™) is a Useful Agent in the Salvage Treatment of Adults with Relapsed/refractory Philadelphia Positive Acute Leukemias , 2003, Hematology.
[11] S. Sohn,et al. Cardiac morbidity in advanced chronic myelogenous leukaemia patients treated by successive allogeneic stem cell transplantation with busulphan/cyclophosphamide conditioning after imatinib mesylate administration , 2003, British journal of haematology.
[12] J. Ford,et al. Practical management of patients with chronic myeloid leukemia receiving imatinib. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] J. Ford,et al. Imatinib treatment: specific issues related to safety, fertility, and pregnancy. , 2003, Seminars in hematology.
[14] Francisco Cervantes,et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. , 2003, The New England journal of medicine.
[15] C. Chuah,et al. Imatinib mesylate (STI-571) given concurrently with nonmyeloablative stem cell transplantation did not compromise engraftment and resulted in cytogenetic remission in a patient with chronic myeloid leukemia in blast crisis , 2003, Bone Marrow Transplantation.
[16] N. Kröger,et al. Imatinib mesylate (STI571) in preparation for allogeneic hematopoietic stem cell transplantation and donor lymphocyte infusions in patients with Philadelphia-positive acute leukemias , 2003, Leukemia.
[17] A. Gratwohl,et al. Increasing use of reduced intensity conditioning transplants: report of the 2001 EBMT activity survey , 2002, Bone Marrow Transplantation.
[18] H. Gschaidmeier,et al. Therapy with imatinib mesylate (Glivec) preceding allogeneic stem cell transplantation (SCT) in relapsed or refractory Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL) , 2002, Leukemia.
[19] C. Miething,et al. Effects of imatinib on bone marrow engraftment in syngeneic mice , 2002, Leukemia.
[20] D. Marin,et al. Factors affecting duration of survival after onset of blastic transformation of chronic myeloid leukemia. , 2002, Blood.
[21] K. Antman,et al. Imatinib mesylate--a new oral targeted therapy. , 2002, The New England journal of medicine.
[22] Sigrid Stroobants,et al. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study , 2001, The Lancet.
[23] C. Sawyers,et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. , 2001, The New England journal of medicine.
[24] S. Woolf,et al. An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the American Society of Hematology. , 1999, Blood.
[25] J Hermans,et al. Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation , 1998, The Lancet.
[26] H. Heimpel,et al. Survival with bone marrow transplantation versus hydroxyurea or interferon for chronic myelogenous leukemia. The German CML Study Group. , 1998, Blood.
[27] J. Melo,et al. The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells. , 1997, Blood.
[28] E D Thomas,et al. 1994 Consensus Conference on Acute GVHD Grading. , 1995, Bone marrow transplantation.
[29] G. McDonald,et al. Veno-occlusive Disease of the Liver and Multiorgan Failure after Bone Marrow Transplantation: A Cohort Study of 355 Patients , 1993, Annals of Internal Medicine.
[30] J. Klein,et al. Bone marrow transplantation for leukemia following a new busulfan and cyclophosphamide regimen , 1987 .
[31] H. Deeg,et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. , 1986, The New England journal of medicine.
[32] B. Druker,et al. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy , 2002, Leukemia.
[33] S. Gupta,et al. Hepatocyte transplantation: emerging insights into mechanisms of liver repopulation and their relevance to potential therapies. , 1999, Journal of hepatology.
[34] J. Klein,et al. Bone marrow transplantation for leukemia following a new busulfan and cyclophosphamide regimen. , 1987, Blood.